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Abstract
Background Impact of telemedicine with remote patient monitoring (RPM) in implantable cardioverter–defibrillator (ICD) 
patients on clinical outcomes has been investigated in various clinical settings with divergent results. However, role of RPM 
on patient-reported-outcomes (PRO) is unclear. The INFRARED-ICD trial aimed to investigate the effect of RPM in addi-
tion to standard-of-care on PRO in a mixed ICD patient cohort.
Methods and results Patients were randomized to RPM (n = 92) or standard in-office-FU (n = 88) serving as control group 
(CTL). At baseline and on a monthly basis over 1 year, study participants completed the EQ-5D questionnaire for the primary 
outcome Quality of Life (QoL), the Hospital Anxiety and Depression Scale, and the Florida Patient Acceptance Survey 
questionnaire for secondary outcomes. Demographic characteristics (82% men, mean age 62.3 years) and PRO at baseline 
were not different between RPM and CTL. Primary outcome analysis showed that additional RPM was not superior to CTL 
with respect to QoL over 12 months [+ 1.2 vs. + 3.9 points in CTL and RPM group, respectively (p = 0.24)]. Pre-specified 
analyses could not identify subgroups with improved QoL by the use of RPM. Neither levels of anxiety (− 0.4 vs. − 0.3, 
p = 0.88), depression (+ 0.3 vs. ± 0.0, p = 0.38), nor device acceptance (+ 1.1 vs. + 1.6, p = 0.20) were influenced by addi-
tional use of RPM.
Conclusion The results of the present study show that PRO were not improved by RPM in addition to standard-of-care FU. 
Careful evaluation and planning of future trials in selected ICD patients are warranted before implementing RPM in routine 
practice.
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Introduction
Shocks of implantable cardioverter–defibrillators (ICDs) for 
ventricular arrhythmias are associated with worse patient-
reported outcomes including feelings of depression, anxiety, 
and loss of control [1]. Although therapy with ICDs is proven 
to be effective in the prevention of sudden cardiac death [2], 
its use in clinical practice is currently facing problems of 
limited resources in the health care system. This led to the 
development of new ICD follow-up (FU) strategies with 
active patient involvement, namely remote patient monitor-
ing (RPM) for telemetric transmission of ICD data. How-
ever, the majority of recent large randomized-controlled trials 
has failed to provide consistent evidence for the superiority 
on hard clinical endpoints, i.e., mortality [3–5]. Additional 
potential effects of RPM, such as improvement of patient-
reported outcomes, are not well investigated [6]. Therefore, 
we investigated the effect of RPM in addition to standard 
in-office ICD follow-up on patient-reported outcomes com-
pared to patients receiving standard in-office ICD follow-up 
only. The change of Quality of Life (QoL) over 12 months 
(measured by EQ-5D-index) served as the primary endpoint.
Methods
Trial design and participants
This controlled longitudinal randomized open-label trial 
was conducted at the Ludwig Maximilians-University of 
Munich, Campus Grosshadern. Design of the trial, includ-
ing questionnaire use, and an assessor-blinded analysis were 
performed in collaboration with the Bielefeld University, 
School of Public Health. The study was approved by the 
local ethics committee (registration no. 166-11) and regis-
tered at clinicaltrials.gov (Identifier: NCT02888028).
All patients aged 18 years and older presenting to our 
clinic for new implantation or replacement of an ICD due to 
battery depletion were eligible for inclusion (n = 321). The 
decision which system to implant was related to the discre-
tion of the treating physician considering the different pacing 
and VT discrimination algorithms, sensor techniques, size, 
and battery longevity of the individual systems. The brands 
of the ICD systems implanted were as follows: Medtronic 
n = 71; Biotronik n = 49; St. Jude Medical n = 34; and Boston 
Scientific n = 26. Following assessment of exclusion criteria 
(refusal to participate, insufficient language skills, inability 
to comply with the protocol, a history of severe psychiatric 
illness, or missing availability of a standard land phone line) 
and informed consent, a total of 180 patients were included 
in the study and followed for 12 months (see Fig. 1).
Intervention
Patients were randomly assigned to either routine standard 
in-office FU serving as control group (CTL) or the inter-
ventional arm with RPM in addition to in-office FU. Using 
a block randomization provided by the Bielefeld University, 
the University of Munich was provided with the randomiza-
tion result after successful enrollment of the patient.
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In both groups, standard in-office FU every 3–6 months 
was performed. Patients in the RPM group received an RPM 
system in addition to the standard in-office FU to evaluate 
the “pure” additional effect of RPM. Patient-reported out-
comes were measured at baseline and monthly during the 
12-month FU period.
Remote patient monitoring implementation 
and training process
Patients were informed of the advantages and disadvantages 
of the different means of ICD follow-up, with a special 
regard on RPM surveillance (advantages: reduced number 
of in-office visits, option of extended follow-up periods, 
early detection of ICD malfunctions, and use of heart-failure 
monitoring tools; disadvantages: no option of telemetric ICD 
re-programming).
According to the different brands of implanted ICDs, four 
different RPM systems were used in the present study, those 
were the CareLink™ system (Medtronic), HomeMonitor-
ing™ (Biotronik), the Latitude™ (Boston Scientific) and 
the Merlin.net™ system (St. Jude Medical). Data that were 
transmitted comprised battery status, sensing parameters, 
stimulation and high-voltage impedance, information on 
applied ICD therapies (shocks and/or antitachycardia pac-
ing), and transmission of additional, device-specific diagnosis 
Fig. 1  CONSORT statement 
flow diagram according to study 
protocol for both study cohorts. 
For the intention-to-treat 
analysis, n = 86 patients in the 
RPM group and n = 81 patients 
in the CTL group were analyzed 
with respect to patient-reported 
outcomes. CTL control, RPM 
remote patient monitoring
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algorithms, like information on heart rate profile/variabil-
ity, percentage of stimulation or atrial fibrillation burden. 
Except for the HomeMonitoring™ system (Biotronik™), 
that enabled daily automatic data transmission, the manual 
transmissions with the other RPM systems were scheduled 
in 3 month intervals. The details on the used RPM systems 
with a brief description of the individual features and the 
workflow for RPM transmissions can be found in the online 
supplement. Depending on the assigned RPM system with 
different initialization requirements patients were instructed 
over a 30–60-min period about the contents and the usage 
of the RPM package (monitor, wand, power supply, and tel-
ephone cables), including a detailed description of monitor 
set-up if indicated. In patients with missing transmissions 1 
month after enrollment, one single attempt was performed 
to contact those study participants. All these patients were 
explicitly notified regarding the failed transmission and with 
a phone call re-instructed (30 min) on the initializing process.
Assessment of patient‑reported outcomes
Patients were blinded to their assigned study group for base-
line assessment of patient-reported outcomes. Patients com-
pleted the set of questionnaires on the day after ICD implan-
tation. During the FU period of 12 months, postal surveys 
were performed on a monthly basis intended to assess dis-
creet changes of patient-reported outcomes and especially to 
allow for the detection of temporary undulations, e.g., due 
to cardiac decompensation or ICD shocks [7]. Patients with 
a missing response (defined as delay > 10 days in expected 
time of questionnaire return) were contacted by a study 
nurse (up to three reminder phone calls). After a maximum 
of three reminder calls without a response, this set of ques-
tionnaires was considered lost to follow-up.
Instruments for assessment of QoL, levels 
of anxiety/depression, and device acceptance
Outcomes of this trial were measured by the use of patient-
reported data obtained from validated questionnaires. To 
assess QoL, the generic and validated EQ-5D-3L question-
naire by the EuroQol consortium was used [8]. Anxiety 
and depression levels were measured using the Hospital 
Anxiety and Depression Scale (HADS-D) [9]. Device 
acceptance, referring to the psychological accommodation 
and understanding of the device, was measured using the 
18-item Florida Patient Acceptance Survey (FPAS) [10].
Health‑related quality of life
The generic EuroQol (EQ-5D-3L) questionnaire was 
designed by the EuroQoL Group as a standardized and 
generic instrument (cross-disease) for the measurement of 
health-related QoL. It is often used in combination with 
disease-specific tools. Generic instruments are designed 
to measure overall health states and allow comparisons 
across patients with different diseases and the general 
population. Therefore, they are suitable to support health 
policy decisions. The EQ-5D comprises five dimen-
sions (mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression) on a three-point scale. The 
responses indicate three levels of severity (no problems/
some or moderate problems/extreme problems) within a 
particular EQ-5D dimension. Using an algorithm based 
on eleven European studies, each health state can be trans-
ferred into a single index value between 0 (lowest QoL) 
and 100 (highest QoL) [11]. The ability to convert self-
classification responses into a single index score makes the 
EQ-5D practical for clinical and economic evaluation [12]. 
Mean levels of QoL in a German cross-section cohort are 
reported in the literature with 77.4 ± 19 points in the over-
all population [13] and with 76.29 ± 4.48 points in a subset 
of elderly people with an age above 65 years, respectively 
[14]. The average test–retest-reliability is 0.75 (Pearson’s 
R) [15].
Anxiety and depression
Anxiety and depression levels were measured using the Hos-
pital Anxiety and Depression Scale (HADS). The HADS 
questionnaire consists of 14 items related to anxiety and 
depression in which patients respond using a 4-point Likert 
scale [16]. Scores range from 0 to 21 points for both anxiety 
and depression. With respect to the subscales anxiety and 
depression, 0–7 indicates non-cases, 8–10 indicates doubtful 
cases, and 11–21 points indicates manifest depression/anxi-
ety. The reliability/internal consistency (Cronbachs alpha) 
for the HADS is α = 0.8 for both depression and anxiety [17].
Device acceptance
Device acceptance refers to the psychological accommo-
dation and understanding of the device and the derivation 
of benefit in terms of biopsychosocial functioning. Device 
acceptance was measured using the 18-item Florida Patient 
Acceptance Survey (FPAS) [10]. The FPAS is one of only 
a few standardized and validated instruments to measure 
device acceptance. A 5-point Likert scale was used, rang-
ing from “strongly disagree” (1 point) to “strongly agree” 
(5 points) [18]. The 18 items contribute to four subscales: 
(1) return to function, (2) device-related distress, (3) posi-
tive appraisal, and (4) body image concerns. The three addi-
tional questions are filler items. A higher score indicates 
greater device acceptance. There are no absolute cut-off 
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values for the FPAS, but based on a prior validation study, a 
score ≤ 65.5 is considered a correlate of poor device accept-
ance [18]. The internal consistency ranges from α = 0.74 to 
α = 0.89 [10].
Data analysis and statistical methods
Continuous variables are expressed as means ± standard 
deviations (SD) unless otherwise noted and categorical 
variables are presented as frequencies. To exclude sample 
distortions, all test procedures and sociodemographic vari-
ables of the RPM and CTL groups were tested for equality 
of variances by Levene’s test, and baseline group differences 
were assessed using independent t tests for continuous vari-
ables and Chi-square tests for categorical variables.
Unless specified otherwise, all analyses were conducted 
using univariate ANOVAs with repeated measurement and 
a Bonferroni post hoc test. To determine the squared sum of 
the canonical correlations, total Pillai’s trace was calculated. 
This corresponds to the sum of the “explained” variance 
in the outcome variable accounted for by the effect of the 
independent variables. This method was chosen based on its 
more conservative/robust fashion for smaller sample sizes.
Binary logistic regression models were used to analyze 
the relative chance of an improvement in QoL between both 
study arms in pre-defined subgroups to identify patients 
where additional RPM improved QoL. All changes were 
measured based on an individual level. Thus, we calculated 
first the individual mean change over time and then used 
those individual means to create a group mean.
We calculated odds ratios for the subgroups sex, presence 
of CRT device, ICD implantation indication (primary vs. 
secondary prevention), type of enrollment (new implanta-
tion vs. generator replacement), and ICD shocks [none vs. 
any (both appropriate and inappropriate)]. In addition, the 
median age of 67 years served as cut-off value for the age 
sub-analysis. A dichotomized QoL variable was created 
to serve as the outcome variable in the regression models, 
equaling “QoL increased”, when QoL increased between 
baseline and FU measurements and “QoL not increased” 
when mean QoL decreased or remained unchanged. All 
covariates included in the regression model were selected 
a priori based on clinical knowledge of their influence on 
patient-reported outcomes in ICD cohorts. Missing values 
were processed using a conservative approach and imputed 
by the last observation carried forward method and last 
observation carried backward method, respectively. A 
two-tailed p-value of < 0.05 was considered statistically 
significant.
Patients could only be evaluated if they had at least 
one questionnaire completed. Our pre-specified modified 
intention-to-treat (ITT) analysis was, therefore, adjusted 
accordingly to include all patients who were randomized 
according to inclusion and exclusion criteria and had com-
pleted at least one questionnaire. An additional per-protocol 
analysis included patients that underwent the intervention 
(in-office FU with RPM) over the study period of 12 months 
and performed at least one successful transmission with the 
RPM system.
Table 1  Baseline patient characteristics
Values are absolute numbers and percentages unless otherwise indi-
cated
CRT cardiac resynchronization therapy, ICD implantable cardio-
verter/defibrillator, NYHA denotes New York Heart Association
*Hypertrophic cardiomyopathy; Brugada Syndrome; Long-QT syn-
drome; Arrhythmogenic right ventricular cardiomyopathy; idiopathic 
ventricular fibrillation
Baseline Remote 
monitoring 
group
Control 
group
Number of subjects (n) 86 81
Characteristics
Male gender, n (%) 69 (80.2) 68 (84.0)
Age at implantation, mean (SD) 61.5 (14.2) 63.0 (15.3)
Ejection fraction, mean % (SD) 42.3 (17.0) 37.5 (15.3)
NYHA at implantation, n (%)
 1 30 (34.9) 35 (43.2)
 2 32 (37.2) 29 (35.8)
 3–4 24 (27.9) 16 (19.7)
CRT, n (%) 31 (36.0) 29 (35.8)
Primary prevention, n (%) 51 (59.3) 51 (63.0)
Type of ICD
 Single and dual chambers, n (%) 58 (67.5) 53 (65.5)
 CRT defibrillator, n (%) 28 (32.6) 28 (34.6)
Device replacements, n (%) 16 (18.6) 14 (17.3)
Atrial fibrillation, n (%) 32 (37.2) 38 (46.9)
Previous myocardial infarction, n (%) 24 (27.9) 23 (28.4)
Stroke, n (%) 3 (3.5) 7 (8.6)
Renal insufficiency, n (%) 28 (32.6) 34 (42.0)
Chronic obstructive lung disease, n (%) 5 (5.8) 6 (7.4)
Diabetes, n (%) 16 (18.6) 17 (21.0)
Coronary artery disease, n (%) 35 (40.7) 40 (49.4)
Dilated cardiomyopathy, n (%) 34 (39.5) 29 (35.8)
Other cardiac condition*, n (%) 18 (20.9) 12 (14.8)
Antidepressant medication, n (%) 11 (12.8) 9 (11.1)
Smoking behavior
 Active smoker, n (%) 9 (10.5) 12 (14.8)
 Ex-smoker, n (%) 13 (15.1) 23 (28.4)
Patient-reported outcomes
 Quality of Life, mean (SD) 72.9 (21.1) 77.6 (19.9)
 Depression, mean (SD) 4.6 (3.9) 3.9 (3.9)
 Anxiety, mean (SD) 5.2 (4.0) 4.7 (3.8)
 Device acceptance, mean (SD) 72.0 (18.4) 75.4 (16.9)
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The power calculation suggested that for an 80% chance 
of detecting a 0.05 significant change of quality of life 
assuming a medium effect size of ƒ = 0.25, 98 subjects would 
be needed (Fcrit = 3.94). Allowing for a conservative esti-
mate of a 35–40% drop-out (postal survey for a 12 × 1 month 
period) and a 7% mortality rate, a total sample size of 180 
participants had been calculated. Statistical analyses were 
performed using SPSS for Windows software (Version 24.0; 
SPSS Institute, Chicago, Ill.) and open source Software R 
(CRAN-R 3.2.3).
Results
Baseline characteristics
The ITT cohort comprised 86 patients in the RPM and 
81 patients in the CTL group (see Fig. 1). Table 1 depicts 
the baseline clinical and demographic characteristics of 
the study population. Study participants were mainly male 
(> 80% in both groups); 40.7% and 49.4% had a history 
of coronary artery disease in the RPM and CTL group, 
respectively, and the majority of participants (RPM 59.3% 
vs. CTL 63.0%) were provided with an ICD for primary 
prevention. About 81% in the RPM and 82.7% in the CTL 
group were enrolled after de-novo ICD implantation, while 
the remaining individuals were enrolled for generator 
replacement. Prior ICD shocks were equally distributed 
[RPM: mean 0.5; SD: 1.8; CTL: 0.2; SD: 0.8; (p = 0.15)]. 
In the RPM group, only 62 of 86 patients (72%) were able 
to initialize the system by performing at least one success-
ful transmission.
Psychological baseline status
Baseline values for mean QoL scores did not differ between 
the RPM (72.9; SD: 21.1) and CTL group (77.6; SD: 19.9). 
The mean levels of depression and anxiety were comparable 
between the RPM and CTL groups (depression: 4.6; SD: 
3.9 vs. 3.9; SD: 3.9, p = 0.35; anxiety: 5.2; SD: 4.0 vs. 4.7; 
SD: 3.8, p = 0.42, respectively). Baseline values of device 
acceptance were equally distributed between the RPM and 
CTL groups (72.0; SD: 16.9 and 75.4; SD: 15.7, p = 0.69, 
respectively, see Table 1).
Questionnaire return rates
Of the possible 2340 questionnaires that could have 
been returned (180 patients, 13 each), the return rate was 
71%, with 65% of patients having returned more than ten 
Fig. 2  Influence of remote patient monitoring on patient-reported 
outcomes over 12 months. QoL was not improved by the use of RPM 
compared to the CTL group (a). RPM implementation failed to have 
significant impact on the levels of depression (b), anxiety (c), and 
device acceptance (d). CTL control, QoL quality of life, RPM remote 
patient monitoring;
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questionnaires. Chi-square tests displayed an equally distrib-
uted return rate between the CTL and RPM groups of 70% 
and 72%, respectively (χ2 < 1; p = n.s.).
Primary endpoint—changes in QoL over 12 months
The analysis of the primary outcome showed a mean change 
of QoL over 12 months of 1.2 points in the CTL and 3.9 
points in the RPM group, respectively. The difference 
between both groups (intergroup comparison) was not sta-
tistically significant (p = 0.24, Fig. 2a).
The analysis assessing the impact of the pre-defined sub-
groups failed to show a significant interaction in one of the 
subgroups suggesting no difference in outcome by one of the 
two treatment strategies (Fig. 3). Noteworthy, the sub-anal-
ysis regarding type of enrollment showed a trend towards 
a benefit in patients undergoing de-novo implantation vs. 
patients after device replacement. A non-pre-specified post 
hoc sub-analysis (Figure S1, online supplement) assess-
ing the impact of the mode of data transmission revealed 
that patients equipped with fully automatic transmission 
RPM systems seem to significantly benefit from this com-
pletely user independent, automatic technique (OR 2.52, 
CI 1.3–5.60; p = 0.02), while non-automatic systems with 
manual transmission are showing a neutral result compared 
to the CTL arm.
Changes of QoL within the two study groups 
(intragroup comparison)
In addition to the analysis of the primary endpoint between 
both treatment groups (intergroup comparison), we per-
formed a separate intragroup comparison of the QoL change 
within each group over time vs. baseline. We observed a 
moderate, but significant increase in QoL within the RPM 
group (3.9 points, p = 0.04), while there was no significant 
change in QoL in the CTL group (1.2 points, p = 0.5) over 
12 months (Fig. 2a). This slight increase of 3.9 points in the 
RPM group could be attributed to the RPM subgroup capa-
ble of fully automatic data transmission (Biotronik Home-
Monitoring™, mean increase of 7.6 ± 20.0 points).
Per protocol analysis for the primary endpoint
Based on the fact that 28% of participants never activated 
RPM, we performed a per-protocol analysis for the patients 
with a working RPM system. The results of the per-proto-
col analysis including 62 patients in the RPM group (only 
patients who had used/activated the RPM) and 81 patients 
in the CTL group confirmed that an additional FU with 
successfully initialized RPM did not add any benefit with 
respect to the primary outcome of QoL in RPM or CTL 
group (mean change: + 5 points and + 1.2 points, respec-
tively; p = 0.63).
Fig. 3  Chance of improvement of QoL depending in clinical/demo-
graphic subgroups. No specific subgroup could be identified hav-
ing significant effect on the impact of additional RPM on QoL. 
ICD  implantable cardioverter/defibrillator; CRT cardiac resynchroni-
zation therapy, QoL quality of life
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Secondary endpoints
In addition, we aimed to assess the influence of RMP on 
secondary measures. These analyses revealed no significant 
group differences for depression, anxiety, and device accept-
ance (see Fig. 2b–d).
Discussion
Relevance of RPM on daily patient care
The INFRARED-ICD trial was specifically designed to 
investigate the impact of RPM in ICD recipients on patient-
reported outcomes. The results of the present study failed 
to demonstrate a significant benefit of RPM on QoL, levels 
of anxiety and depression, and device acceptance over the 
course of 12 months. Furthermore, subgroup analyses failed 
to identify individuals where the use of RPM improved QoL.
The neutral results of this study with respect to the pri-
mary endpoint constitute an important finding since the 
use of RPM is currently under intense discussion in face of 
mainly negative results from previous large controlled trials 
on the effect of RPM on clinical endpoints [5]. The large 
prospective MORE-CARE study (n = 865) failed to show a 
significant benefit of RPM in CRT patients with respect to 
mortality and cardiovascular/device-related hospitalizations 
[4]. The REM-HF study confirmed these results, showing 
that RPM did not reduce the incidence of cardiovascular 
events in a heart-failure cohort [5]. In contrast, the IN-TIME 
and TIM-HF-2 trials were able to show a potential benefit on 
clinical outcomes by RPM surveillance [19–21]. Regarding 
economic aspects, RPM bears the potential to be a cost-
efficient alternative to regular in-office device interrogations 
[22, 23]. Given these controversial results, more research on 
other aspects of RPM is warranted, with high priority on the 
effect of RPM on factors such as psychological aspects of 
the patients’ well-being [24–26].
Baseline measures of patient‑reported outcomes
Baselines measures for QoL were 72.9 ± 21.1 and 
77.6 ± 19.9 points in the RPM and the control cohort, 
respectively (Table 1). Comparing those QoL levels with 
the German overall population (77.4 ± 19 points [13]) sug-
gests no significant impairment of QoL in the study cohort 
at baseline. In line with these results, baseline measures for 
anxiety (5.2 ± 4.0 and 4.7 ± 3.8) and depression (4.6 ± 3.9 
and 3.9 ± 3.9) in the RPM and the control group did not 
suggest clinically relevant anxiety/depression levels when 
compared to the existing literature (German general popula-
tion: values of 4.4 ± 3.3 and 4.8 ± 4.0 for anxiety and depres-
sion, respectively [27]). The levels for device acceptance 
(72.0 ± 18.4 and 75.4 ± 16.9) for the RPM and control group 
were also comparable to a reported FPAS score (76.0 points) 
in a mixed ICD patient cohort [10] and did not suggest any 
significant impairment of device acceptance at baseline.
Comparison to previous studies
It is difficult to compare our results to previously published 
literature, since data on patient-reported outcomes in pre-
specified RPM cohorts are scarce [28, 29]. A few rand-
omized trials included QoL as a secondary measure [28, 
30–32]. In a sub-analysis of the randomized EVOLVO trial, 
the authors observed that RPM was associated with a more 
favorable change in QoL compared to the standard-of-care 
group [28]. Results from the REFORM trial comparing 
regular 3-month in-office FUs vs. in-office FU once every 
12 months under RPM surveillance support the theory that 
extended 12-month in-office FUs with additional RPM can 
result in increased QoL [33]. One single-center pilot study 
actually demonstrated better outcomes with respect to QoL 
in patients with more frequent in-office device interrogations 
vs. sole follow-up by RPM [30]. The authors speculate that 
the patients’ skepticism about the ease of use of the RPM 
system and their perception that RPM could impair in-office 
patient care.
In contrast, a secondary analysis of the MORE-CARE 
study failed to show a difference in QoL in heart-failure 
patients who underwent RPM-guided vs. regular in-office 
FU over a 12-month period [31]. In line with these neu-
tral results, a sub-analysis of the ECOST trial failed to 
demonstrate a benefit in QoL in the RPM group [32]. The 
just recently published REMOTE-CIED trial specifically 
designed to assess health status in a heart-failure cohort 
confirms the majority of former studies not identifying any 
specific benefit of RPM surveillance on patient-reported 
outcomes [6].
Taken divergent results of prior trials, it is important to 
address the role of different outcome measurement instru-
ments and patient cohorts. The EVOLVO and MORE-CARE 
trials in heart-failure patients assessed QoL by the Minne-
sota Living with Heart-Failure Questionnaire, a disease-
specific instrument validated in patients with heart failure 
with preserved and reduced ejection fraction. With respect 
to RPM studies on mixed patient cohorts, the REFORM 
[33] and ECOST trials [22] used the SF-36 questionnaire to 
assess QoL. Although its generic character, the results of the 
SF-36 cannot be adopted one to one as results of both ques-
tionnaires cannot be considered fully interchangeably [34] 
which further confirms that different outcome measurement 
instruments and patient cohorts hamper the comparability 
of the results. It is of crucial importance to keep in mind 
that the RPM systems used in our study have meanwhile 
been significantly further developed with respect to ease of 
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use (i.e., initialization process). Especially, the feature of 
automatic wireless data transmission has meanwhile been 
applied to each of those systems.
To further understand the discrepancies between previ-
ous trials, we analyzed intragroup changes, and observed a 
significant increase in QoL within the RPM group over the 
12-month FU, with just a trend to baseline values in the CTL 
group. This might suggest a potential benefit with respect 
to QoL in the RPM group, which could not be confirmed in 
our intergroup comparison (RPM vs. CTL group) either due 
to a concomitant QoL improvement of the CTL group or to 
the low patient number in this study. We were able to show 
that this slight increase was mainly attributable to the RPM 
group with automatic data transmission which points at the 
potential benefit of this novel wireless technique without the 
need for any user interaction on patient-reported outcomes. 
This was further supported by our non-pre-specified sub-
analysis investigating the impact of the mode of transmis-
sion on the individual benefit from RPM. We could show 
that patients equipped with fully automatic RPM systems 
seemed to benefit from telemetric data transmission with 
respect to QoL, while manual transmission showed a neutral 
result. As meanwhile all ICD manufactures offer wireless 
RPM solutions capable of fully automatic data transmission, 
there is the urgent need for future studies aiming to elucidate 
the effect of RPM systems equipped with the modern-user 
friendly, automatic features on psychological outcomes.
Role of patients’ motivation and successful RPM 
implementation
Studies with negative results on the impact of RPM on 
clinical endpoints suggest that the lack of patients’ motiva-
tion and unsuccessful implementation of the RPM system 
could be a potential confounder [3, 35]. In the present study, 
28% of patients with RPM system failed to initialize the 
system. Our results are consistent with the previous large 
randomized trials, showing that 20–24% of patients never 
activated the RPM system [3, 36]. We, therefore, tested the 
hypothesis that benefit of RPM on patient-reported outcomes 
might rely on a working RPM system which could not be 
confirmed by the results of the per-protocol analysis of our 
study.
Secondary endpoints
In addition to the primary outcome, we sought to investigate 
the effect of RPM on anxiety, depression, and device accept-
ance. It is hypothesized that the use of RPM has the potential 
to reduce psychological distress based on studies showing a 
high patient satisfaction and the feeling of additional safety 
[23, 29, 37]. Nevertheless, our analysis failed to show a ben-
efit of RPM on the levels of anxiety and depression.
Device acceptance is known to influence the levels of 
psychological distress as well as QoL, which thus represents 
a major determinant of psychological well-being in patients 
with ICDs [18]. In the present study, the intervention of 
additional RPM in ICD patients did not translate into better 
device acceptance which suggests that additional technical 
challenges associated with new technology might lead to 
mental overload in patients counterbalancing any positive 
effects.
Pre‑specified subgroup analysis
Since there is evidence that ICD shocks are associated with 
impaired QoL, we hypothesized that patients with a history 
of ICD shocks might benefit from RPM [38] which could 
not be confirmed in the present study. It might be specu-
lated that the overall number of patients with appropriate 
or inappropriate shocks was too low to provide a significant 
difference between RPM and CTL group. With respect to 
implantation indication, our study confirmed results from 
a previous meta-analysis demonstrating no impact of the 
initial implantation indication on levels of QoL [39]. Except 
for pre-existing ICD experience, no significant difference 
with respect to QoL could be identified in the pre-speci-
fied subgroup analyses (patients with vs. w/o ICD shocks; 
primary vs. secondary implantation indication). In fact, 
patients undergoing de-novo implantation showed a trend 
of better QoL by additional RPM. This finding suggests that 
ICD-naïve patients might be more open-minded towards 
new techniques potentially simplifying their lives, e.g., by 
extending the in-office FU intervals or by simply transmit-
ting their data to the hospital in case of suspected events 
like an ICD shock. Pre-existing ICD FU experience might 
have blunted the positive effect of RPM as those patients can 
be assumed to have already adapted well to the implanted 
device or actually demanded the personal contact to a doc-
tor during an in-office follow-up. This hypothesis has to be 
further evaluated in future studies.
Potential relevance and future implications
In addition to available data [3–6], our study adds addi-
tional evidence that at the moment it seems hard to justify 
additional costs for RPM based on the lack of benefit at 
the moment. However, taking our results on QoL, showing 
also no negative effect, and taken the beneficial results from 
the positive In-Time and TIM-HF2 trial, RPM might be at 
least a very good alternative approach in selected patients. 
Therefore, the broad implementation of RPM usage might 
require additional research to identify subgroups of RPM 
 Clinical Research in Cardiology
1 3
responders or specific diagnostic and therapeutic algorithms 
related to RPM [19, 20].
Limitations
Our study has some limitations. As baseline values for QoL 
assessed by the EQ-5D were unexpectedly high, we cannot 
rule out the phenomenon of a ceiling effect as the already 
high baseline value might hamper a significant change in 
QoL between the groups with the final result of inability to 
emerge a significant difference between the study groups. 
The rationale for specifically choosing the EQ-5D was its 
shortness and simplicity to achieve a high response rate, 
despite the fact other known disease-specific instruments 
might have had provided better discrimination abilities for 
slight differences in QoL.
We only included ICD patients, and therefore, the results 
may not be applied to pacemaker patients capable of telem-
etric interrogation. Furthermore, it can be speculated that 
psychologically distressed patients, specifically those with 
highest levels of anxiety and depression, declined study par-
ticipation in terms of a selection bias prior to enrollment.
The short interrogation intervals of 1 month initially 
intended to assess discreet changes of patient-reported 
outcomes might constitute a limitation of our study. Such 
intense interrogations can result in tiring of the participants 
and making them remember their previous answer which can 
influence the results.
The rather small patient sample size of this trial and the 
use of a conservative imputation method (LOCF) as well 
as the inclusion of patients with only on questionnaire may 
have contributed to an underestimation of the effect of RPM 
on patient-reported outcomes, especially in the pre-defined 
subgroups. Finally, our study results must be seen under 
the aspect that the current RPM systems have been further 
developed providing features that were not applicable in all 
the systems used in our study (i.e., automatic wireless data 
transmission and ease of use of the initialization process). 
This is especially important in view of our post hoc finding 
that the use of the RPM system capable of fully automatic 
data transmission (Biotronik HomeMonitoring™; n = 37 
patients) was associated with a significant benefit of RPM 
usage compared to the CTL group.
Conclusion
At first glance, results from this randomized study on 
patient-reported outcomes in ICD recipients suggest no 
benefit by the use of additional RPM compared to a routine 
follow-up strategy with respect to QoL, anxiety/depression, 
and device acceptance. We were unable to identify any spe-
cific subgroups of patients who were prone to benefit from 
RPM implementation. Nevertheless, considering the neutral 
results of our study, it can be postulated that the approach 
of RPM-assisted ICD follow-up does not impact QoL in a 
negative way. Taken that and several other benefits of RPM, 
which have already been demonstrated (the potential of 
health care utilization [4] or time to clinical decision reduc-
tion [40] or even the chance to improve clinical outcome 
[19]), this telemetric surveillance could become an alterna-
tive approach to standard care with in-office ICD follow-ups. 
With respect to the design of further studies, it is of crucial 
importance that they aim at elucidating the benefit of RPM 
in preselected subgroups as well as at trying to assess the 
benefit of an exclusive RPM surveillance with no (or at least 
only annual) in-office device interrogations.
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